Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, will hold its Annual General Meeting at 11am today at their offices at 3 Robroyston Oval, Nova Business Park, Glasgow, G33 1AP. At the meeting, Jamal Rushdy, CEO of Collagen Solutions will make the following statement:
"Building on a successful fundraise in June, and momentum from our most recent financial year, we remain positive about our outlook and on track with our key initiatives for the year. Our core business is seeing continued growth as expected to support our goal of further improvement on overall financial performance in line with market expectations. We are also progressing with infrastructure projects to increase our capacity for contract manufacturing while we also expand our tissue supply. We are engaged in active dialogue with our notified body regarding our application for CE marking ChondroMimetic®, consistent with our plan to resolve open questions in time to gain approval in the financial year, while the response time or additional questions by the notified body still cannot be guaranteed. Finally, our global R&D team is executing on several key customer product development projects supporting a strong pipeline of contract manufacturing over the next several years."
Collagen Solutions Plc
Jamal Rushdy, CEO
Hilary Spence, CFO
Cenkos Securities Plc (Nominated Adviser and Broker)
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, tissue engineering, and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Collagen Solutions PLC's (LON:COS) Jamal Rushdy and Hilary Spence update Proactive London's Andrew Scott on first half performance - their third consecutive six-month period of double-digit sales growth.
Revenues increased by 14% to £2.23mln in the period ended September 30. Tissue sales more...